Vycor Medical Releases Financial Results for the Three And Six Months Ended June 30, 2026

VYCOR MEDICAL INC (VYCO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Vycor Medical Releases Financial Results for the Three And Six Months Ended June 30, 2026 BOCA RATON, FL (August 14, 2026) – Vycor Medical, Inc. (“Vycor”) (OTCQB—VYCO), today announced financial results for the three and six months ended June 30, 2026. The Company op

Event · Earnings
Original reporting
Published Aug 14, 2026, 8:13 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 14, 2026, 8:27 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$VYCO
Bearish
medium confidence
Mentioned
$VYCO
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$VYCOBearishMed
01

Why it matters

Traders can use the disclosed revenue contraction and operating profit deterioration to update near-term expectations for VBAS commercialization, while separately weighing the potential longer-term credibility boost from additional peer-reviewed clinical publications.

02

Market read

The primary tradable takeaway is the disclosed year-over-year decline in revenue and operating profit for both the quarter and first half of 2026, with international markets driving most of the drop.

03

What to watch

The filing highlights new peer-reviewed VBAS studies (53 total papers), which could support longer-term adoption even as near-term financials weaken.

Relevance 7/10Novelty 7/10Timing: after-hours filing on Aug 14, 2026

Background

This SEC 8-K (Item 2.02) reports Vycor Medical’s financial results for the three and six months ended June 30, 2026, including GAAP and non-GAAP operating metrics and division revenue.

Company-level read

Ticker impact

$VYCOBearishMedium confidence
Context

Vycor Medical reported 3-month revenue of $418,264, down 16% year over year, with GAAP operating profit falling to $6,851.

Expected impact

Near-term downside bias as traders reprice weak top-line and operating profitability trends, especially given the international-market decline.

Evidence & confidence

The filing provides specific GAAP and non-GAAP operating profit declines and revenue contraction for both the quarter and six-month period, which typically pressures microcap sentiment and liquidity.

Market effects

Signals ongoing commercialization pressure for neurosurgical device revenue, with international sales volatility affecting quarterly comparability.

International markets are cited as the main driver of the quarterly revenue decline, implying regional demand softness.

Limited broader market impact expected given the company size and OTCQB listing.

Counterpoint

International sales are described as lumpy, so the quarter’s decline may not reflect sustained demand if large orders shift into later periods.

Key entities

  • VYCOR MEDICAL, INC.

    OTCQB-listed medical device company reporting quarterly and six-month financial results for VBAS and NovaVision.

  • ViewSite Brain Access System (VBAS)

    Primary revenue-generating system for neurosurgeons; revenue declined year over year in the reported periods.

  • NovaVision

    Business in development with small but slightly higher revenue year over year.

Related articles

$VYCOMed

Vycor Medical Releases Financial Results for the Three And Nine Months Ended September 30, 2026

VYCOR MEDICAL INC (VYCO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Vycor Medical Releases Financial Results for the Three And Nine Months Ended September 30, 2026 BOCA RATON, FL (November 13, 2026) – Vycor Medical, Inc. (“Vycor”) (OTCQB—VYCO), today announced financial results for the three and nine months ended September 30, 2026.

$XPMedAI 8/10

XP Q3 2026 slides: asset growth strong, but margin pressure evident

XP Inc. reported Q3 2026 earnings with total client assets up 15% YoY to R$2.2T, but net margins contracted to 26.9%. Revenue grew 8% YoY to R$5.3B, while SG&A expenses rose 12% YoY. Shares fell 4.26% post-earnings. The company is diversifying revenue, with non-investment revenues now 20% of retail revenue. Management expects 10% annual top-line growth in 2027.